User login
SAN DIEGO – The average proportion of ischemic patients who got tissue plasminogen activator within an hour of arriving at participating hospitals increased from 30% before initiation of the Target: Stroke project to 53% afterward. We interviewed Dr. Gregg C. Fonarow about the new phase II of Target: Stroke, launched at the International Stroke Conference, which aims for timely door-to-needle treatment in 75% of stroke patients.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
SAN DIEGO – The average proportion of ischemic patients who got tissue plasminogen activator within an hour of arriving at participating hospitals increased from 30% before initiation of the Target: Stroke project to 53% afterward. We interviewed Dr. Gregg C. Fonarow about the new phase II of Target: Stroke, launched at the International Stroke Conference, which aims for timely door-to-needle treatment in 75% of stroke patients.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
SAN DIEGO – The average proportion of ischemic patients who got tissue plasminogen activator within an hour of arriving at participating hospitals increased from 30% before initiation of the Target: Stroke project to 53% afterward. We interviewed Dr. Gregg C. Fonarow about the new phase II of Target: Stroke, launched at the International Stroke Conference, which aims for timely door-to-needle treatment in 75% of stroke patients.
